United States-based Frazier Healthcare Partners has introduced Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections, it was reported yesterday.
Recida's lead program, RC-01, is a novel, IND-stage LpxC inhibitor intended for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialisation rights to RC-01 from FUJIFILM Toyama Chemical Co Ltd for all territories outside Japan. The company intends to submit an Investigational New Drug (IND) application for the product to the United States Food and Drug Administration (FDA) in the first quarter of 2019.
The product inhibits bacterial LpxC, a key enzyme in Lipid A biosynthesis. It exhibits a broad spectrum of rapid, in vitro and in vivo bactericidal activity against major clinically relevant pathogens such as the Enterobacteriaceae and Pseudomonas aeruginosa.
CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a Boston University global partnership funded by the US has awarded Recida up to USD4.4m to help fund the preparation of an IND application, a Phase 1 trial to be completed in 2019 and drug product manufacturing to support subsequent Phase 2 studies.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial